Advertisement

Vitiligo pp 283-290 | Cite as

Proopiomelanocortin and Related Hormones

  • Markus BöhmEmail author

Core Messages

  • The cutaneous proopiomelanocortin (POMC) system is an important regulatory system, which controls pigmentation, inflammation, and the stress response of the skin.

  • Based on their potent melanotropic effects, selected melanocortin peptides derived from POMC have been tested in the past for their efficacy in vitiligo.

  • To investigate the potential role of the POMC system in the pathogenesis of vitiligo, a limited number of experimental studies have been performed until now. These studies aimed at (a) determining the peripheral blood levels of circulating POMC peptides, (b) examining possible genetic defects of distinct POMC components, and (c) investigating the in situ expression of various components of the POMC system.

Keywords

Single Nucleotide Polymorphism Control Skin Vitiligo Patient Perilesional Skin Peripheral Blood Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reference

  1. 1.
    Abdel-Malek Z, Swope VB, Suzuki I et al (1995) Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 92:1789–1793PubMedCrossRefGoogle Scholar
  2. 2.
    Al-Omari H, al-Sugair S, Ab Hussain A (1989) Intralesional injection of tetracosactid in the treatment of localized viti-ligo. Int J Dermatol 28:682PubMedCrossRefGoogle Scholar
  3. 3.
    Böhm M, Raghunath M, Sunderkotter C et al (2004) Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem 279:6959–6966PubMedCrossRefGoogle Scholar
  4. 4.
    Böhm M, Eickelmann M, Li Z et al (2005) Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulat-ing hormone in human dermal papilla cells. Endocrinology 146:4635–4646PubMedCrossRefGoogle Scholar
  5. 5.
    Böhm M, Wolff I, Scholzen TE et al (2005) Alpha-melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 280:5795–5802PubMedCrossRefGoogle Scholar
  6. 6.
    Böhm M, Luger TA, Tobin DJ, Garcia-Borron JC (2006) Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol 126:1966–1975PubMedCrossRefGoogle Scholar
  7. 7.
    Brzoska T, Luger TA, Maaser C et al (2008) Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immunemediated inflammatory diseases. Endocr Rev 29:581–602PubMedCrossRefGoogle Scholar
  8. 8.
    Caixia T, Daming Z, Xiran L (2001) Levels of beta-endor-phin in the plasma and skin tissue fluids of patients with viti-ligo. J Dermatol Sci 26:62–66PubMedCrossRefGoogle Scholar
  9. 9.
    Cone RD, Lu D, Koppula S et al (1996) The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 51:287–318PubMedGoogle Scholar
  10. 10.
    Eipper BA, Mains RE (1980) Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. Endocr Rev 1:1–27PubMedCrossRefGoogle Scholar
  11. 11.
    Gokhale BB, Gokhale TB (1976) Corticotropin and vitiligo (preliminary observations). Br J Derrmatol 95:329CrossRefGoogle Scholar
  12. 12.
    Graham A, Westerhof W, Thody AJ (1999) The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann NY Acad Sci 885:470–473PubMedCrossRefGoogle Scholar
  13. 13.
    Harrison C, Smart D, Lambert DG (1998) Stimulatory effects of opioids. Br J Anaesth 81:20–28PubMedCrossRefGoogle Scholar
  14. 14.
    Hernández-Pérez E (1979) Vitiligo treated with ACTH. Int J Dermatol 18:578–579PubMedCrossRefGoogle Scholar
  15. 15.
    Hruby VJ, Wilkes BC, Hadley ME et al (1987) Alpha-melanotropin: the minimal active sequence in the frog skin bioassay. J Med Chem 30:2126–2130PubMedCrossRefGoogle Scholar
  16. 16.
    Ichimiya M (1999) Immunohistochemical study of ACTH and alpha-MSH in vitiligo patients successfully treated with a sex steroid-thyroid hormone mixture. J Dermatol 26:502–506PubMedGoogle Scholar
  17. 17.
    Kauser S, Schallreuter KU, Thody AJ et al (2003) Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 120:1073–1080PubMedCrossRefGoogle Scholar
  18. 18.
    Kauser S, Thody AJ, Schallreuter KU et al (2004) Beta-endorphin as a regulator of human hair follicle melanocyte biology. J Invest Dermatol 123:184–195PubMedCrossRefGoogle Scholar
  19. 19.
    Kieffer BL, Evans CJ (2009) Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology, 56(Suppl 1):205–212PubMedCrossRefGoogle Scholar
  20. 20.
    Kingo K, Aunin E, Karelson M et al (2007) Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci 48:113–122PubMedCrossRefGoogle Scholar
  21. 21.
    Kokot A, Sindrilaru A, Schiller M et al (2009) α-Melano-cyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma. Arthritis Rheum 60:592–603PubMedCrossRefGoogle Scholar
  22. 22.
    Lerner AB, McGuire JS (1961) The effect of alpha- and beta melanocyte stimulating hormone on the skin colour of man. Nature 189:176–79PubMedCrossRefGoogle Scholar
  23. 23.
    Lerner AB, Snell RS, Chanco-Turner ML, McGuire JS (1966)Vitiligo and sympathectomy. The effect of sympath-ectomy and alpha-melanocyte stimulating hormone. Arch Dermatol 94:269–278PubMedCrossRefGoogle Scholar
  24. 24.
    Miller MW, Duhl DM, Vrieling H et al (1993) Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 7:454–467PubMedCrossRefGoogle Scholar
  25. 25.
    Mozzanica N, Villa ML, Foppa S et al (1992) Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 26:693–700PubMedCrossRefGoogle Scholar
  26. 26.
    Na GY, Lee KH, Kim MK et al (2003) Polymorphisms in the melanocortin-1 receptor (MC1R) and agouti signaling protein (ASIP) genes in Korean vitiligo patients. Pigment Cell Res 16:383–387PubMedCrossRefGoogle Scholar
  27. 27.
    Pichler R, Sfetsos K, Badics B et al (2006) Vitiligo patients present lower plasma levels of alpha-melanotropin immuno-reactivities. Neuropeptides 40:177–183PubMedCrossRefGoogle Scholar
  28. 28.
    Robbins LS, Nadeau JH, Johnson KR et al (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827–834PubMedCrossRefGoogle Scholar
  29. 29.
    Seidah NG, Benjannet S, Hamelin J et al (1999) The subtili-sin/kexin family of precursor convertases. Emphasis on PC1, PC2/7B2, POMC and the novel enzyme SKI-1. Ann N Y Acad Sci 885:57–74PubMedCrossRefGoogle Scholar
  30. 30.
    Schallreuter KU, Moore J, Wood JM et al (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 4:91–96PubMedCrossRefGoogle Scholar
  31. 31.
    Slominski A, Paus R, Wortsman J (1991) Can some melan-otropins modulate keratinocyte proliferation? J Invest Dermatol 97:747PubMedCrossRefGoogle Scholar
  32. 32.
    Slominski A, Wortsman J, Luger T et al (2000) Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80:979–1020PubMedGoogle Scholar
  33. 33.
    Spencer JD, Gibbons NC, Rokos H et al (2006) Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol 127:411–420PubMedCrossRefGoogle Scholar
  34. 34.
    Spencer JD, Gibbons NC, Böhm M, Schallreuter KU (2008) The Ca2+-binding capacity of epidermal furin is disrupted by H2O2-mediated oxidation in vitiligo. Endocrinology 149:1638–1645PubMedCrossRefGoogle Scholar
  35. 35.
    Spencer JD, Schallreuter KU (2009) Regulation of pigmentation in human epidermal melanocytes by functional high affinity α-MSH/MC4-R signalling. Endocrinology 150:1250–1258PubMedCrossRefGoogle Scholar
  36. 36.
    Széll M, Baltás E, Bodai L et al (2008) The Arg160Trp allele of melanocortin-1 receptor gene might protect against viti-ligo. Photochem Photobiol 84:565–571PubMedCrossRefGoogle Scholar
  37. 37.
    Thody AJ, Ridley K, Penny RJ et al (1983) MSH peptides are present in mammalian skin. Peptides 4:813–816PubMedCrossRefGoogle Scholar
  38. 38.
    Valverde P, Healy E, Jackson I et al (1995) Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11:328–330PubMedCrossRefGoogle Scholar
  39. 39.
    Voisey J, van Daal A (2002) Agouti: from mouse to man, from skin to fat. Pigment Cell Res 15:10–18PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of MünsterMünsterGermany

Personalised recommendations